2-[bis(4-fluorophenyl)methoxy]ethyl chloride | 50366-31-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[bis(4-fluorophenyl)methoxy]ethyl chloride
• 英文别名: 1-[bis(4-fluorophenyl)methoxy]-2-chloroethane；1-[(2-chloroethoxy)(4-fluorophenyl)methyl]-4-fluorobenzene；1-[2-chloroethoxy-(4-fluorophenyl)methyl]-4-fluorobenzene
• CAS: 50366-31-9
• 化学式: C₁₅H₁₃ClF₂O
• 分子量: 282.717
• InChiKey: FFEFFMLVFNFYPA-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C(Press: 0.2 Torr)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[bis(4-fluorophenyl)methoxy]ethyl chloride 在 sodium carbonate 、 sodium iodide 作用下， 以 水 、 丁酮 为溶剂， 反应 48.0h， 生成 伐诺司林
  参考文献：
  名称：

  Scale-Up Synthesis of the Dopamine Uptake Inhibitor GBR-12909

  摘要：

  1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR-12909) is a dopamine uptake inhibitor. The development of a robust process for the preparation of this compound in kilogram quantities is described. The primary aims of the development work were to eliminate chromatographic purifications, to minimize the use of environmentally unacceptable reagents, and to improve the overall yield of the three-step convergent process. These objectives were met, with significant improvements obtained in the key coupling reaction of N-(3-phenylpropyl)piperazine dihydrochloride salt with 1-[bis(4-fluorophenyl)methoxy]-2-chloroethane, which was previously low-yielding and lacking in reproducibility.

  DOI：

  10.1021/op020211j
• 作为产物：
  描述：

  4-氟苯基溴化镁 在 磷酸 作用下， 以 四氢呋喃 、 乙醚 、 甲苯 为溶剂， 反应 49.0h， 生成 2-[bis(4-fluorophenyl)methoxy]ethyl chloride
  参考文献：
  名称：

  First catalytic enantioselective synthesis of the cocaine abuse therapeutic agent (S)-(+)-1-(4-{2-[bis(4-fluorophenyl)methoxy]ethyl}piperazin-1-yl)-2-phenyl-2-propanol

  摘要：

  (S)-(+)-1-(4-{2-[Bis(4-fluorophenyl)methoxy]ethyl} piperazin-1-yl)-2-phenyl-2-propanol, which is a promising candidate as a cocaine abuse therapeutic agent, is prepared in several steps. The key asymmetric step is the catalytic enantioselective addition of dimethylzinc to either 2-chloro or 2-bromoacetophenone catalyzed by the use of different chiral isoborneolsulfonamide ligands in the presence of titanium tetraisopropoxide. The synthesis of a new isoborneolsulfonamide ligand bearing a trifluromethyl. substituent and its use in this addition is also presented. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.12.028

文献信息

• Design, synthesis and in vitro activity of 1,4-disubstituted piperazines and piperidines as triple reuptake inhibitors
  作者：Suresh Paudel、Srijan Acharya、Goo Yoon、Kyeong-Man Kim、Seung Hoon Cheon

  DOI：10.1016/j.bmc.2017.02.051

  日期：2017.4

  currently appear to be the potential target in the management of these disorders. In this study, homologation and bioisosterism techniques have been used in the designing of new 1,4-disubstituted piperazines and piperidines. These derivatives were synthesized and evaluated as potential triple reuptake inhibitors for studying the structure-activity relationships. The most advanced compound, 1-(4-(5-

  单胺转运蛋白调节着单胺神经递质的浓度，这对于重要的生理过程至关重要，其功能障碍会导致多种中枢神经系统疾病。目前，单胺转运蛋白似乎是这些疾病管理中的潜在靶标。在这项研究中，同源性和生物立体异构技术已被用于设计新的1,4-二取代哌嗪和哌啶。这些衍生物被合成并评估为潜在的三重再摄取抑制剂，用于研究结构-活性关系。最先进的化合物1-（4-（5-苯甲酰基-1H-四唑-1-基）丁基）-4-（3-苯丙基）哌嗪（2i）在体外测试中能够抑制单胺神经递质的再摄取（对于5-HT，IC50 = 158.7nM，对于NE，IC50 = 99nM，对于DA，IC50 = 97.5nM）。
• 9-amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds
  申请人：Hoechst-Roussel Pharmaceuticals Inc.

  公开号：US04695573A1

  公开（公告）日：1987-09-22

  There are disclosed compounds having the formula ##STR1## wherein n is 1, 2 or 3; X is hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, trifluoromethyl, NHCOR.sub.2 where R.sub.2 is loweralkyl, or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl; R is hydrogen or loweralkyl; R.sub.1 is hydrogen, loweralkyl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, furylloweralkyl, thienylloweralkyl, oxygen-bridged arylloweralkyl, oxygen-bridged diarylloweralkyl, oxygen-bridged furylloweralkyl or oxygen-bridged thienylloweralkyl; Y is C.dbd.O or CR.sub.5 OH where R.sub.5 is hydrogen or loweralkyl; Z is CH.sub.2 or C.dbd.CR.sub.6 R.sub.7 where R.sub.6 and R.sub.7 are independently hydrogen or loweralkyl; or Y and Z taken together is CR.sub.5 .dbd.CH where CR.sub.5 and CH correspond to Y and Z respectively; an optical antipode thereof, or a pharmaceutically acceptable acid addition salt thereof, which are useful for enhancing memory, methods for synthesizing them, and pharmaceutical compositions comprising an effective memory enhancing amount of such a compound.

  披露了具有以下结构式的化合物##STR1##其中n为1、2或3；X为氢、较低烷基、较低烷氧基、卤素、羟基、硝基、三氟甲基、NHCOR.sub.2，其中R.sub.2为较低烷基，或NR.sub.3 R.sub.4，其中R.sub.3和R.sub.4独立地为氢或较低烷基；R为氢或较低烷基；R.sub.1为氢、较低烷基、二较低烷基氨基较低烷基、芳基较低烷基、二芳基较低烷基、呋喃基较低烷基、噻吩基较低烷基、氧桥芳基较低烷基、氧桥二芳基较低烷基、氧桥呋喃基较低烷基或氧桥噻吩基较低烷基；Y为C.dbd.O或CR.sub.5 OH，其中R.sub.5为氢或较低烷基；Z为CH.sub.2或C.dbd.CR.sub.6 R.sub.7，其中R.sub.6和R.sub.7独立地为氢或较低烷基；或Y和Z一起为CR.sub.5 .dbd.CH，其中CR.sub.5和CH分别对应于Y和Z；其光学对映体，或其药学上可接受的酸盐，用于增强记忆，合成它们的方法，以及包含有效增强记忆量的这种化合物的药物组合物。
• 1,4-disubstituted piperazines
  申请人：Novo Nordisk A/S

  公开号：US05276035A1

  公开（公告）日：1994-01-04

  A disubstituted piperazine compound having the formula ##STR1## wherein R.sup.1 is halogen, methoxy, C.sub.1-6 -alkyl or trifluoromethyl, and R.sup.2 is methyl or substituted C.sub.1-8 -alkyl, C.sub.3-8 -alkenyl or C.sub.3-8 -cycloalkyl, where substituents may be hydroxy-, keto- or oximino-groups in any position leading to a stable tertiary amine; or R.sup.2 is a straight or branched C.sub.1-8 -alkyl or C.sub.3-8 -alkenyl, which in any position may be substituted as above, but is terminally substituted with one of the following groups: cyano, optionally C.sub.1-4 -alkoxy-substituted C.sub.1-4 -alkoxy, dimethoxy, optiontionally substituted phenoxy, phosphonic acid, thienyl, furyl, oxazoline, isoxazole, oxadiazole, where the optional substitution is represented by C.sub.1-6 -alkyl or phenyl, provided that when cyano is the only substituent in R.sup.2, R.sup.2 must contain at least four carbon atoms, and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of mental disorders in which a dopaminergic deficit is implicated.

  一种二取代哌嗪化合物，其化学式为##STR1##其中R.sup.1为卤素、甲氧基、C.sub.1-6-烷基或三氟甲基，R.sup.2为甲基或取代的C.sub.1-8-烷基、C.sub.3-8-烯基或C.sub.3-8-环烷基，取代基可以是羟基、酮基或肟基，位于任何位置导致稳定的三级胺；或者R.sup.2为直链或支链的C.sub.1-8-烷基或C.sub.3-8-烯基，在任何位置可以如上述取代，但末端取代为以下之一的基团：氰基、可选的C.sub.1-4-烷氧基取代的C.sub.1-4-烷氧基、二甲氧基、可选取代的苯氧基、膦酸、噻吩基、呋喃基、噁唑啉、异噁唑啉、噁二唑啉，其中可选的取代由C.sub.1-6-烷基或苯基表示，但当氰基是R.sup.2中唯一的取代基时，R.sup.2必须至少含有四个碳原子，并且其药学上可接受的酸盐。这些化合物在治疗涉及多巴胺缺乏的精神障碍中是有用的。
• N-aryl-piperazinealkanamides useful for protecting hearts from
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04766125A1

  公开（公告）日：1988-08-23

  Novel N-aryl-piperazinealkanamides, having particular substituents attached to one of the carbon atoms of the piperazine ring, which compounds are useful to protect hearts from myocardial injury caused by ischaemia, anoxia or hypoxia.

  新型N-芳基哌嗪烷酰胺，其中特定取代基连接到哌嗪环的一个碳原子上，这些化合物对于保护心脏免受缺血、缺氧或低氧引起的心肌损伤是有用的。
• (Benzhydryloxyethylpiperidyl) aliphatic acid derivatives and their use
  申请人：Sankyo Company, Limited

  公开号：US05294623A1

  公开（公告）日：1994-03-15

  Compounds of formula (I): ##STR1## in which: R.sup.1 and R.sup.2 are independently alkyl, alkoxy, trifluoromethyl, nitro or halogen; A is an aliphatic hydrocarbon group having from 2 to 8 carbon atoms whose chain contains at least 2 carbon atoms in a linear chain between the piperidine group and --COOH, said group optionally being unsaturated; and m and n are independently 0, 1, 2 or 3; and pharmaceutically acceptable salts and esters thereof have been found to have valuable anti-histamine properties without the usual side effects of anti-histamines. Methods of preparing the compounds are also provided.

  化合物的式子（I）：##STR1## 其中：R.sup.1和R.sup.2是独立的烷基，烷氧基，三氟甲基，硝基或卤素基；A是具有2至8个碳原子的脂肪族烃基，其链在哌啶基和--COOH之间至少包含2个碳原子的线性链，该基团可以是不饱和的；m和n独立地为0、1、2或3；以及其药学上可接受的盐和酯被发现具有有价值的抗组胺特性，而没有抗组胺药物的常见副作用。还提供了制备这些化合物的方法。